CD90- (Thy-1-) High Selection Enhances Reprogramming Capacity of Murine Adipose-Derived Mesenchymal Stem Cells
Background. Mesenchymal stem cells (MSCs), including adipose tissue-derived mesenchymal stem cells (ADSC), are multipotent and can differentiate into various cell types possessing unique immunomodulatory features. Several clinical trials have demonstrated the safety and possible efficacy of MSCs in...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2013-01-01
|
Series: | Disease Markers |
Online Access: | http://dx.doi.org/10.1155/2013/392578 |
id |
doaj-ed3a782f5dfd468eaa6ff5fa5341da3c |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Koichi Kawamoto Masamitsu Konno Hiroaki Nagano Shimpei Nishikawa Yoshito Tomimaru Hirofumi Akita Naoki Hama Hiroshi Wada Shogo Kobayashi Hidetoshi Eguchi Masahiro Tanemura Toshinori Ito Yuichiro Doki Masaki Mori Hideshi Ishii |
spellingShingle |
Koichi Kawamoto Masamitsu Konno Hiroaki Nagano Shimpei Nishikawa Yoshito Tomimaru Hirofumi Akita Naoki Hama Hiroshi Wada Shogo Kobayashi Hidetoshi Eguchi Masahiro Tanemura Toshinori Ito Yuichiro Doki Masaki Mori Hideshi Ishii CD90- (Thy-1-) High Selection Enhances Reprogramming Capacity of Murine Adipose-Derived Mesenchymal Stem Cells Disease Markers |
author_facet |
Koichi Kawamoto Masamitsu Konno Hiroaki Nagano Shimpei Nishikawa Yoshito Tomimaru Hirofumi Akita Naoki Hama Hiroshi Wada Shogo Kobayashi Hidetoshi Eguchi Masahiro Tanemura Toshinori Ito Yuichiro Doki Masaki Mori Hideshi Ishii |
author_sort |
Koichi Kawamoto |
title |
CD90- (Thy-1-) High Selection Enhances Reprogramming Capacity of Murine Adipose-Derived Mesenchymal Stem Cells |
title_short |
CD90- (Thy-1-) High Selection Enhances Reprogramming Capacity of Murine Adipose-Derived Mesenchymal Stem Cells |
title_full |
CD90- (Thy-1-) High Selection Enhances Reprogramming Capacity of Murine Adipose-Derived Mesenchymal Stem Cells |
title_fullStr |
CD90- (Thy-1-) High Selection Enhances Reprogramming Capacity of Murine Adipose-Derived Mesenchymal Stem Cells |
title_full_unstemmed |
CD90- (Thy-1-) High Selection Enhances Reprogramming Capacity of Murine Adipose-Derived Mesenchymal Stem Cells |
title_sort |
cd90- (thy-1-) high selection enhances reprogramming capacity of murine adipose-derived mesenchymal stem cells |
publisher |
Hindawi Limited |
series |
Disease Markers |
issn |
0278-0240 1875-8630 |
publishDate |
2013-01-01 |
description |
Background. Mesenchymal stem cells (MSCs), including adipose tissue-derived mesenchymal stem cells (ADSC), are multipotent and can differentiate into various cell types possessing unique immunomodulatory features. Several clinical trials have demonstrated the safety and possible efficacy of MSCs in organ transplantation. Thus, stem cell therapy is promising for tolerance induction. In this study, we assessed the reprogramming capacity of murine ADSCs and found that CD90 (Thy-1), originally discovered as a thymocyte antigen, could be a useful marker for cell therapy. Method. Murine ADSCs were isolated from B6 mice, sorted using a FACSAria cell sorter by selection of CD90Hi or CD90Lo, and then transduced with four standard factors (4F; Oct4, Sox2, Klf4, and c-Myc). Results. Unsorted, CD90Hi-sorted, and CD90Lo-sorted murine ADSCs were reprogrammed using standard 4F transduction. CD90Hi ADSCs showed increased numbers of alkaline phosphatase-positive colonies compared with CD90Lo ADSCs. The relative reprogramming efficiencies of unsorted, CD90Hi-sorted, and CD90Lo-sorted ADSCs were 100%, 116.5%, and 74.7%, respectively. CD90Hi cells were more responsive to reprogramming. Conclusion. CD90Hi ADSCs had greater reprogramming capacity than CD90Lo ADSCs, suggesting that ADSCs have heterogeneous subpopulations. Thus, CD90Hi selection presents an effective strategy to isolate a highly suppressive subpopulation for stem cell-based tolerance induction therapy. |
url |
http://dx.doi.org/10.1155/2013/392578 |
work_keys_str_mv |
AT koichikawamoto cd90thy1highselectionenhancesreprogrammingcapacityofmurineadiposederivedmesenchymalstemcells AT masamitsukonno cd90thy1highselectionenhancesreprogrammingcapacityofmurineadiposederivedmesenchymalstemcells AT hiroakinagano cd90thy1highselectionenhancesreprogrammingcapacityofmurineadiposederivedmesenchymalstemcells AT shimpeinishikawa cd90thy1highselectionenhancesreprogrammingcapacityofmurineadiposederivedmesenchymalstemcells AT yoshitotomimaru cd90thy1highselectionenhancesreprogrammingcapacityofmurineadiposederivedmesenchymalstemcells AT hirofumiakita cd90thy1highselectionenhancesreprogrammingcapacityofmurineadiposederivedmesenchymalstemcells AT naokihama cd90thy1highselectionenhancesreprogrammingcapacityofmurineadiposederivedmesenchymalstemcells AT hiroshiwada cd90thy1highselectionenhancesreprogrammingcapacityofmurineadiposederivedmesenchymalstemcells AT shogokobayashi cd90thy1highselectionenhancesreprogrammingcapacityofmurineadiposederivedmesenchymalstemcells AT hidetoshieguchi cd90thy1highselectionenhancesreprogrammingcapacityofmurineadiposederivedmesenchymalstemcells AT masahirotanemura cd90thy1highselectionenhancesreprogrammingcapacityofmurineadiposederivedmesenchymalstemcells AT toshinoriito cd90thy1highselectionenhancesreprogrammingcapacityofmurineadiposederivedmesenchymalstemcells AT yuichirodoki cd90thy1highselectionenhancesreprogrammingcapacityofmurineadiposederivedmesenchymalstemcells AT masakimori cd90thy1highselectionenhancesreprogrammingcapacityofmurineadiposederivedmesenchymalstemcells AT hideshiishii cd90thy1highselectionenhancesreprogrammingcapacityofmurineadiposederivedmesenchymalstemcells |
_version_ |
1716809714933694464 |
spelling |
doaj-ed3a782f5dfd468eaa6ff5fa5341da3c2020-11-24T20:47:31ZengHindawi LimitedDisease Markers0278-02401875-86302013-01-0135557357910.1155/2013/392578392578CD90- (Thy-1-) High Selection Enhances Reprogramming Capacity of Murine Adipose-Derived Mesenchymal Stem CellsKoichi Kawamoto0Masamitsu Konno1Hiroaki Nagano2Shimpei Nishikawa3Yoshito Tomimaru4Hirofumi Akita5Naoki Hama6Hiroshi Wada7Shogo Kobayashi8Hidetoshi Eguchi9Masahiro Tanemura10Toshinori Ito11Yuichiro Doki12Masaki Mori13Hideshi Ishii14Department of Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, JapanDepartment of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, JapanDepartment of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, JapanDepartment of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, JapanDepartment of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, JapanDepartment of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, JapanDepartment of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, JapanDepartment of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, JapanDepartment of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, JapanDepartment of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, JapanDepartment of Surgery and Institute for Clinical Research, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima 737-0023, JapanDepartment of Complementary and Alternative Medicine, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, JapanDepartment of Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, JapanDepartment of Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, JapanDepartment of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, JapanBackground. Mesenchymal stem cells (MSCs), including adipose tissue-derived mesenchymal stem cells (ADSC), are multipotent and can differentiate into various cell types possessing unique immunomodulatory features. Several clinical trials have demonstrated the safety and possible efficacy of MSCs in organ transplantation. Thus, stem cell therapy is promising for tolerance induction. In this study, we assessed the reprogramming capacity of murine ADSCs and found that CD90 (Thy-1), originally discovered as a thymocyte antigen, could be a useful marker for cell therapy. Method. Murine ADSCs were isolated from B6 mice, sorted using a FACSAria cell sorter by selection of CD90Hi or CD90Lo, and then transduced with four standard factors (4F; Oct4, Sox2, Klf4, and c-Myc). Results. Unsorted, CD90Hi-sorted, and CD90Lo-sorted murine ADSCs were reprogrammed using standard 4F transduction. CD90Hi ADSCs showed increased numbers of alkaline phosphatase-positive colonies compared with CD90Lo ADSCs. The relative reprogramming efficiencies of unsorted, CD90Hi-sorted, and CD90Lo-sorted ADSCs were 100%, 116.5%, and 74.7%, respectively. CD90Hi cells were more responsive to reprogramming. Conclusion. CD90Hi ADSCs had greater reprogramming capacity than CD90Lo ADSCs, suggesting that ADSCs have heterogeneous subpopulations. Thus, CD90Hi selection presents an effective strategy to isolate a highly suppressive subpopulation for stem cell-based tolerance induction therapy.http://dx.doi.org/10.1155/2013/392578 |